Bayer AG

Equities

Market Closed - Xetra Other stock markets 11:35:12 2026-06-05 am EDT			5-day change	1st Jan Change
36.16 ^EUR	+1.69%		-1.01%	-2.30%

Jun. 05	Study: Bayer's Finerenone slows progression of chronic kidney disease	RE
Jun. 05	Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease	CI

Published on 05/12/2026 at 05:50 am EDT - Modified on 05/12/2026 at 07:50 am EDT

S&P Capital IQ

Presenter Speech
Michael Preuss (Executives)

Well, good morning, everybody, and welcome to our media update for the first quarter 2026. Many thanks for joining us today.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jun. 05	Study: Bayer's Finerenone slows progression of chronic kidney disease	RE
Jun. 05	Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease	CI
Jun. 05	BAYER AG : UBS maintains a Buy rating	ZD
Jun. 05	UBS maintains 'Buy' rating on Bayer - Target 52 euros	DP
Jun. 05	Bayer CEO: Hormuz Blockade Threatens Harvests - Criticism of Germany as a Business Hub	RE
Jun. 04	Top cases on the US Supreme Court's docket	RE
Jun. 03	Wall Street's Record Highs Are Starting to Look a Little Narrow
Jun. 03	AlphaValue/Baader Europe Upgrades Bayer to Buy, Trims PT	MT
Jun. 03	Mwb Says Bayer Valuation Discounts US Legal Overhang; Buy Rating Kept	MT
Jun. 03	Bayer Rating Maintained at Buy as BofA Notes Transfer of Roundup Class Action Lawsuit	MT
Jun. 03	Europe wants to get back into the technology race
Jun. 02	Bayer Denies Restructuring Plans Despite Monsanto Lawsuits	MT
Jun. 02	Bayer says no plans to restructure despite litigation threat	RE
Jun. 02	Health Care Down as Traders Rotate to Other Defensive Sectors -- Health Care Roundup	DJ
Jun. 02	Germany's Blue-chip DAX Index Gains; Eurozone Inflation Accelerates	MT